| Primary |
| Urinary Tract Infection |
34.8% |
| Hypertension |
12.3% |
| Cystitis |
6.7% |
| Atrial Fibrillation |
4.8% |
| Dyslipidaemia |
3.9% |
| Pyrexia |
3.7% |
| Prostatitis |
3.5% |
| Abdominal Pain |
3.0% |
| Prophylaxis |
3.0% |
| Depression |
2.8% |
| Diarrhoea |
2.6% |
| Epilepsy |
2.6% |
| Pain |
2.6% |
| Bronchitis |
2.4% |
| Drug Use For Unknown Indication |
2.4% |
| Pyelonephritis |
2.2% |
| Anxiety |
1.9% |
| Arthralgia |
1.7% |
| Dysuria |
1.7% |
| Insomnia |
1.5% |
|
| Tendonitis |
8.8% |
| Drug Exposure During Pregnancy |
8.0% |
| Pyrexia |
7.2% |
| Tendon Disorder |
7.2% |
| Toxic Skin Eruption |
7.2% |
| Cytolytic Hepatitis |
6.4% |
| Drug Eruption |
6.4% |
| International Normalised Ratio Increased |
6.4% |
| Rectal Haemorrhage |
4.8% |
| Drug Interaction |
4.0% |
| Jaundice |
4.0% |
| Myalgia |
4.0% |
| Paralysis |
4.0% |
| Acute Generalised Exanthematous Pustulosis |
3.2% |
| Interstitial Lung Disease |
3.2% |
| Leukocytoclastic Vasculitis |
3.2% |
| Renal Failure Acute |
3.2% |
| Rhabdomyolysis |
3.2% |
| Vomiting |
3.2% |
| Intra-uterine Death |
2.4% |
|
| Secondary |
| Urinary Tract Infection |
23.9% |
| Drug Use For Unknown Indication |
15.4% |
| Pyelonephritis |
12.3% |
| Product Used For Unknown Indication |
12.2% |
| Prophylaxis |
4.1% |
| Hypertension |
3.8% |
| Epilepsy |
3.4% |
| Pyrexia |
2.9% |
| Abdominal Pain |
2.6% |
| Diabetes Mellitus |
2.3% |
| Bronchitis |
2.2% |
| Upper Respiratory Tract Inflammation |
2.2% |
| Atrial Fibrillation |
1.9% |
| Diarrhoea |
1.9% |
| Cystitis |
1.8% |
| Type 2 Diabetes Mellitus |
1.6% |
| Renal Colic |
1.5% |
| Bronchopneumopathy |
1.3% |
| Depression |
1.3% |
| Dyslipidaemia |
1.2% |
|
| Tendon Disorder |
51.4% |
| Drug Eruption |
5.2% |
| Cytolytic Hepatitis |
3.5% |
| Thrombocytopenia |
3.5% |
| Urticaria |
3.5% |
| Pyrexia |
2.9% |
| Renal Failure Acute |
2.9% |
| Vomiting |
2.9% |
| Condition Aggravated |
2.3% |
| Haemolytic Anaemia |
2.3% |
| Leukopenia |
2.3% |
| Pancreatitis Acute |
2.3% |
| Urinary Tract Infection |
2.3% |
| Vulvovaginal Dryness |
2.3% |
| Hyponatraemia |
1.7% |
| Myalgia |
1.7% |
| Pancytopenia |
1.7% |
| Pseudomembranous Colitis |
1.7% |
| Red Blood Cell Count Decreased |
1.7% |
| Rhabdomyolysis |
1.7% |
|
| Concomitant |
| Drug Use For Unknown Indication |
32.7% |
| Product Used For Unknown Indication |
11.0% |
| Urinary Tract Infection |
9.2% |
| Hypertension |
8.5% |
| Hepatitis C |
6.2% |
| Rheumatoid Arthritis |
4.8% |
| Diabetes Mellitus |
2.9% |
| Epilepsy |
2.6% |
| Prophylaxis |
2.6% |
| Depression |
2.5% |
| Anaemia |
2.2% |
| Unevaluable Event |
2.1% |
| Ascites |
1.8% |
| Gastrooesophageal Reflux Disease |
1.8% |
| Multiple Myeloma |
1.6% |
| Osteoporosis |
1.6% |
| Pain |
1.6% |
| Cystitis |
1.5% |
| Sleep Disorder |
1.5% |
| Essential Hypertension |
1.3% |
|
| Stevens-johnson Syndrome |
9.9% |
| Tremor |
7.7% |
| Vomiting |
7.7% |
| Renal Failure |
6.6% |
| Renal Impairment |
6.6% |
| Neutropenia |
5.5% |
| Upper Limb Fracture |
5.5% |
| White Blood Cell Count Decreased |
5.5% |
| Anaemia |
4.4% |
| Portal Vein Thrombosis |
4.4% |
| Respiratory Failure |
4.4% |
| Toxic Skin Eruption |
4.4% |
| Visual Impairment |
4.4% |
| Deep Vein Thrombosis |
3.3% |
| Hepatic Encephalopathy |
3.3% |
| Jaundice |
3.3% |
| Oedema Peripheral |
3.3% |
| Pruritus |
3.3% |
| Pulmonary Embolism |
3.3% |
| Pyrexia |
3.3% |
|
| Interacting |
| Drug Use For Unknown Indication |
34.8% |
| Urinary Tract Infection |
13.0% |
| Atrial Fibrillation |
8.7% |
| Chronic Myeloid Leukaemia |
8.7% |
| Depression |
8.7% |
| Abdominal Pain Upper |
4.3% |
| Cystitis |
4.3% |
| Hiatus Hernia |
4.3% |
| Multiple Sclerosis |
4.3% |
| Myocardial Ischaemia |
4.3% |
| Pyelonephritis |
4.3% |
|
| International Normalised Ratio Increased |
22.2% |
| Urinary Tract Infection |
22.2% |
| Drug Interaction |
11.1% |
| Fall |
11.1% |
| Liver Function Test Abnormal |
11.1% |
| Rhabdomyolysis |
11.1% |
| Vomiting |
11.1% |
|
